Positron Emission Tomography Based Elucidation of the Enhanced Permeability and Retention Effect in Dogs with Cancer Using Copper-64 Liposomes

ACS Nano

Volumn 9, Issue 7, 2015, Pages 6985-6995

  Hansen, Anders E ^a,b   Petersen, Anncatrine L ^a   Henriksen, Jonas R ^a   Boerresen, Betina ^c   Rasmussen, Palle ^a   Elema, Dennis R ^a   Rosenschöld, Per Munck Af ^b   Kristensen, Annemarie T ^c   Kjær, Andreas ^b   Andresen, Thomas L ^a  

^a TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^b Rigshospitalet   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

cancer; drug delivery; EPR effect; imaging; liposomes; nanomedicine; nanoparticles

Indexed keywords

ANIMALS; COPPER; DISEASES; DRUG DELIVERY; IMAGING TECHNIQUES; LIPOSOMES; MEDICAL NANOTECHNOLOGY; NANOPARTICLES; TUMORS;

CANCER; CLINICAL PRACTICES; ENHANCED PERMEABILITY AND RETENTION EFFECT; ENHANCED PERMEABILITY AND RETENTION EFFECTS; EPR EFFECT; HIGH RESOLUTION ANALYSIS; PEGYLATED LIPOSOMES; TUMOR ACCUMULATION;

POSITRON EMISSION TOMOGRAPHY;

COPPER; LIPOSOME; MACROGOL DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

ANIMAL; CARCINOMA; CHEMISTRY; COMPUTER ASSISTED TOMOGRAPHY; DOG; FEMALE; MALE; MULTIMODAL IMAGING; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING; VETERINARY;

ANIMALS; CARCINOMA; COPPER RADIOISOTOPES; DOGS; FEMALE; LIPOSOMES; MALE; MULTIMODAL IMAGING; POLYETHYLENE GLYCOLS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84934337555     PISSN: 19360851     EISSN: 1936086X     Source Type: Journal    
DOI: 10.1021/acsnano.5b01324     Document Type: Article

References (33)

1. Barenholz, Y. Doxil(R)-the First FDA-approved Nano-drug: Lessons Learned J. Controlled Release 2012, 160, 117-134
2. Hrkach, J.; Von Hoff, D.; Ali, M. M.; Andrianova, E.; Auer, J.; Campbell, T.; De Witt, D.; Figa, M.; Figueiredo, M.; Horhota, A. Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile Sci. Transl. Med. 2012, 4, 128ra39
3. Matsumura, Y.; Maeda, H. A New Concept for Macromolecular Therapeutics in Cancer Chemotherapy: Mechanism of Tumoritropic Accumulation of Proteins and the Antitumor Agent Smancs Cancer Res. 1986, 46, 6387-6392
4. Bangham, A. D. Surrogate Cells or Trojan Horses. The Discovery of Liposomes BioEssays 1995, 17, 1081-1088
5. Iyer, A. K.; Khaled, G.; Fang, J.; Maeda, H. Exploiting the Enhanced Permeability and Retention Effect for Tumor Targeting Drug Discovery Today 2006, 11, 812-818
6. Zhang, L.; Gu, F. X.; Chan, J. M.; Wang, A. Z.; Langer, R. S.; Farokhzad, O. C. Nanoparticles in Medicine: Therapeutic Applications and Developments Clin. Pharm. Ther. 2008, 83, 761-769
7. Folkman, J. Fundamental Concepts of the Angiogenic Process Curr. Mol. Med. 2003, 3, 643-651
8. Hanahan, D.; Weinberg, R. A. Hallmarks of Cancer: The Next Generation Cell 2011, 144, 646-674
9. Maeda, H.; Bharate, G. Y.; Daruwalla, J. Polymeric Drugs for Efficient Tumor-Targeted Drug Delivery Based on EPR-Effect Eur. J. Pharm. Biopharm. 2009, 71, 409-419
10. Fang, J.; Nakamura, H.; Maeda, H. The EPR effect: Unique Features of Tumor Blood Vessels for Drug Delivery, Factors Involved, and Limitations and Augmentation of the Effect Adv. Drug Delivery Rev. 2011, 63, 136-151
11. Denison, T. A.; Bae, Y. H. Tumor Heterogeneity and its Implication for Drug Delivery J. Controlled Release 2012, 164, 187-191
12. Connolly, D. T.; Heuvelman, D. M.; Nelson, R.; Olander, J. V.; Eppley, B. L.; Delfino, J. J.; Siegel, N. R.; Leimgruber, R. M.; Feder, J. Tumor Vascular Permeability Factor Stimulates Endothelial Cell Growth and Angiogenesis J. Clin. Invest. 1989, 84, 1470-1478
13. Minko, T.; Kopeckova, P.; Pozharov, V.; Jensen, K. D.; Kopecek, J. The Influence of Cytotoxicity of Macromolecules and of VEGF Gene Modulated Vascular Permeability on the Enhanced Permeability and Retention Effect in Resistant Solid Tumors Pharm. Res. 2000, 17, 505-514
14. Safra, T. Cardiac Safety of Liposomal Anthracyclines Oncologist 2003, 8, 17-24
15. Harrington, K. J.; Mohammadtaghi, S.; Uster, P. S.; Glass, D.; Peters, A. M.; Vile, R. G.; Stewart, J. S. Effective Targeting of Solid Tumors in Patients with Locally Advanced Cancers by Radiolabeled Pegylated Liposomes Clin. Cancer Res. 2001, 7, 243-254
16. Presant, C. A.; Blayney, D.; Proffitt, R. T.; Turner, A. F.; Williams, L. E.; Nadel, H. I.; Kennedy, P.; Wiseman, C.; Gala, K.; Crossley, R. J. Preliminary report: Imaging of Kaposi Sarcoma and Lymphoma in AIDS with Indium-111-labelled Liposomes Lancet 1990, 335, 1307-1309
17. Khalifa, A.; Dodds, D.; Rampling, R.; Paterson, J.; Murray, T. Liposomal Distribution in Malignant Glioma: Possibilities for Therapy Nucl. Med. Commun. 1997, 18, 17-23
18. Presant, C. A.; Proffitt, R. T.; Turner, A. F.; Williams, L. E.; Winsor, D.; Werner, J. L.; Kennedy, P.; Wiseman, C.; Gala, K.; McKenna, R. J. Successful Imaging of Human Cancer with Indium-111-labeled Phospholipid Vesicles Cancer 1988, 62, 905-911
19. Paoloni, M.; Khanna, C. Translation of New Cancer Treatments from Pet Dogs to Humans Nat. Rev. Cancer 2008, 8, 147-156
20. Gambhir, S. S. Molecular Imaging of Cancer with Positron Emission Tomography Nat. Rev. Cancer 2002, 2, 683-693
21. Phelps, M. E.; Hoffman, E. J.; Mullani, N. A.; Ter-Pogossian, M. M. Application of Annihilation Coincidence Detection to Transaxial Reconstruction Tomography J. Nucl. Med. 1975, 16, 210-224
22. Seo, J. W.; Qin, S.; Mahakian, L. M.; Watson, K. D.; Kheirolomoom, A.; Ferrara, K. W. Positron Emission Tomography Imaging of the Stability of Cu-64 labeled Dipalmitoyl and Distearoyl Lipids in Liposomes J. Controlled Release 2011, 151, 28-34
23. Willmann, J. K.; van Bruggen, N.; Dinkelborg, L. M.; Gambhir, S. S. Molecular Imaging in Drug Development Nat. Rev. Drug Discovery 2008, 7, 591-607
24. Petersen, A. L.; Binderup, T.; Rasmussen, P.; Henriksen, J. R.; Elema, D. R.; Kjaer, A.; Andresen, T. L. 64Cu Loaded Liposomes as Positron Emission Tomography Imaging Agents Biomaterials 2011, 32, 2334-2341
25. Hansen, A. E.; McEvoy, F.; Engelholm, S. A.; Law, I.; Kristensen, A. T. FDG PET/CT Imaging in Canine Cancer Patients Vet. Radiol. Ultrasound 2011, 52, 201-206
26. Phillips, W. T. Delivery of Gamma-Imaging Agents by Liposomes Adv. Drug Delivery Rev. 1999, 37, 13-32
27. Gabizon, A.; Shmeeda, H.; Barenholz, Y. Pharmacokinetics of Pegylated Liposomal Doxorubicin: Review of Animal and Human Studies Clin. Pharmacokinet. 2003, 42, 419-436
28. Gabizon, A. A. Stealth Liposomes and Tumor Targeting: One Step Further in the Quest for the Magic Bullet Clin. Cancer Res. 2001, 7, 223-225
29. Harrington, K. J.; Rowlinson-Busza, G.; Syrigos, K. N.; Abra, R. M.; Uster, P. S.; Peters, A. M.; Stewart, J. S. Influence of Tumour Size on Uptake of (111)ln-DTPA-Labelled Pegylated Liposomes in a Human Tumour Xenograft Model Br. J. Cancer 2000, 83, 684-688
30. Petersen, A. L.; Binderup, T.; Jølck, R. I.; Rasmussen, P.; Henriksen, J. R.; Pfeifer, A. K.; Kjaer, A.; Andresen, T. L. Positron Emission Tomography Evaluation of Somatostatin Receptor Targeted 64Cu-TATE-Liposomes in a Human Neuroendocrine Carcinoma Mouse Model J. Controlled Release 2012, 160, 254-263
31. Cheng, C. J.; Saltzman, W. M. Nanomedicine: Downsizing Tumour Therapeutics Nat. Nanotechnol. 2012, 7, 346-347
32. Manzoor, A. A.; Lindner, L. H.; Landon, C. D.; Park, J. Y.; Simnick, A. J.; Dreher, M. R.; Das, S.; Hanna, G.; Park, W.; Chilkoti, A. Overcoming Limitations in Nanoparticle Drug Delivery: Triggered, Intravascular Release To Improve Drug Penetration into Tumors Cancer Res. 2012, 72, 5566-5575
33. Gillies, R. J.; Verduzco, D.; Gatenby, R. A. Evolutionary Dynamics of Carcinogenesis and Why Targeted Therapy Does Not Work Nat. Rev. Cancer 2012, 12, 487-493